CD19 and neoplasm: Thirdly, we conducted clinical relevance study of LIGHT and αCD3, and employed B16 tumor cells with human CD19 antigen (hCD19-B16) and murine T cells with anti-human CD19 scFv (hαCD19-mCAR-T cells) to simulate clinical practice as far as possible.